SCHEMBL21150147

SCHEMBL21150147

CC(C)S(=O)(=O)c1ccccc1CNc1nc(Nc2ccc(N3CCC(O)CC3)cc2)nc2ccsc12

nearest known ligand 0.54

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 4/20 0.54
▸ ALK Q9UM73 2/20 0.51
▸ PTK2 Q05397 4/20 0.46
▸ STAT6 P42226 2/20 0.44
▸ JAK2 O60674 2/20 0.44
▸ BRD4 O60885 1/20 0.44
▸ TTK P33981 2/20 0.43
▸ LRRK2 Q5S007 1/20 0.43
▸ FES P07332 1/20 0.43
▸ FLT3 P36888 1/20 0.43
▸ JAK3 P52333 1/20 0.42
▸ EGFR P00533 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19867315 0.92 IRAK4 (0.56) IRAK4ALKPTK2STAT6JAK2
SCHEMBL19867342 0.91 BRD4 (0.53) IRAK4ALKPTK2STAT6JAK2
SCHEMBL21100192 0.88 ALK (0.65) IRAK4ALKPTK2JAK2BRD4
SCHEMBL19921119 0.85 PTK2 (0.46) IRAK4ALKPTK2STAT6JAK2
SCHEMBL19867312 0.82 PTK2 (0.61) IRAK4ALKPTK2STAT6JAK2
SCHEMBL21099691 0.80 ALK (0.67) IRAK4ALKPTK2JAK2TTK
SCHEMBL21150076 0.79 IRAK4 (0.57) IRAK4ALKPTK2JAK2BRD4
SCHEMBL21150115 0.79 ALK (0.63) IRAK4ALKPTK2JAK2BRD4
SCHEMBL19867185 0.78 ALK (0.63) IRAK4ALKPTK2JAK2BRD4
SCHEMBL19921188 0.78 PTK2 (0.52) PTK2STAT6JAK2BRD4JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078213-B2 Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof Hongyun Biotech Co., Ltd. (CN) 2021-08-03 — — US disclosed
US-20200207779-A2 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Hongyun Biotech Co., Ltd. (CN) 2020-07-02 — — US disclosed
US-20190211030-A1 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Hongyun Biotech Co., Ltd. (CN) 2019-07-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190211030-A1 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF ALK, MET, TIE1 IRAK4 701/4885ALK 1/4885PTK2 141/4885
US-20200207779-A2 THIENOPYRIMIDINE COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF ALK, MET, TIE1 IRAK4 701/4885ALK 1/4885PTK2 141/4885
US-11078213-B2 Thienopyrimidine compound, preparation method thereof, pharmaceutical composition and application thereof ALK, MET, TIE1 IRAK4 701/4885ALK 1/4885PTK2 141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback